RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research.
RXR antagonist 1 (compound 6a) shows potent RXR-antagonistic activities at 1 μM[1].
RXR antagonist 1 shows competitive binding to the LBP in hRXRα-LBD, with Ki of 0.384 ± 0.072, Kd of 0.277 ± 0.038, and Ki/Kd of 1.39[1].
The cell permeability of RXR antagonist 1 shows no correlation with RXR-antagonistic activity[1].
















